» Articles » PMID: 34033007

Inhaled Nitric Oxide Improves Pulmonary Hypertension and Organ Functions After Adult Heart Valve Surgeries

Overview
Date 2021 May 25
PMID 34033007
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Pulmonary hypertension during cardiac surgery is associated with increased morbidity and mortality. Inhaled nitric oxide serves as a selective pulmonary vasodilator and has other potential extrapulmonary protective roles. Its effects on pulmonary hypertension and organ functions after adult valve surgeries were evaluated.

Methods: From April 2017 to March 2000, 30 patients received inhaled nitric oxide therapy for pulmonary hypertension during weaning from cardiopulmonary bypass in valvular surgery (iNO group). The group was compared with a control group of 65 patients who developed pulmonary hypertension during weaning from cardiopulmonary bypass in valvular surgery and received conventional therapy from April 2014 to March 2017. Intraoperative hemodynamic changes and postoperative Sequential Organ Failure Assessment (SOFA) score were evaluated.

Results: The inhalation of nitric oxide lowered the pulmonary-to-systemic pressure ratio (Pp/Ps) (p < 0.0001) in the iNO group, and this ratio after the inhalation was significantly lower than that in the control group (p = 0.015). Moreover, norepinephrine requirement was lower in the iNO group than in the control group (p = 0.0060). The SOFA total scores, respiratory scores, coagulation scores, and the increase of renal scores within postoperative 2 days were lower in the iNO group than in the control group (p < 0.0001, p = 0.0002, p = 0.0013, and p = 0.037).

Conclusions: Inhaled nitric oxide therapy ameliorated pulmonary hypertension and improved postoperative respiratory, coagulation, and renal functions in adult valve surgeries.

Citing Articles

Inhaled nitric oxide: can it serve as a savior for COVID-19 and related respiratory and cardiovascular diseases?.

Zhao Y, Li C, Zhang S, Cheng J, Liu Y, Han X Front Microbiol. 2023; 14:1277552.

PMID: 37849924 PMC: 10577426. DOI: 10.3389/fmicb.2023.1277552.


The beneficial use of nitric oxide during cardiopulmonary bypass on postoperative outcomes in children and adult patients: a systematic review and meta-analysis of 2897 patients.

Abouzid M, Roshdy Y, Daniel J, Rzk F, Ismeal A, Hendawy M Eur J Clin Pharmacol. 2023; 79(11):1425-1442.

PMID: 37650923 PMC: 10618325. DOI: 10.1007/s00228-023-03554-9.


Mechanisms of pulmonary vascular dysfunction in pulmonary hypertension and implications for novel therapies.

Christou H, Khalil R Am J Physiol Heart Circ Physiol. 2022; 322(5):H702-H724.

PMID: 35213243 PMC: 8977136. DOI: 10.1152/ajpheart.00021.2022.

References
1.
Denault A, Deschamps A, Tardif J, Lambert J, Perrault L . Pulmonary hypertension in cardiac surgery. Curr Cardiol Rev. 2011; 6(1):1-14. PMC: 2845789. DOI: 10.2174/157340310790231671. View

2.
Pepke-Zaba J, Higenbottam T, Dinh-Xuan A, Stone D, Wallwork J . Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet. 1991; 338(8776):1173-4. DOI: 10.1016/0140-6736(91)92033-x. View

3.
Griffiths M, Evans T . Inhaled nitric oxide therapy in adults. N Engl J Med. 2005; 353(25):2683-95. DOI: 10.1056/NEJMra051884. View

4.
Ichinose F, Roberts Jr J, Zapol W . Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation. 2004; 109(25):3106-11. DOI: 10.1161/01.CIR.0000134595.80170.62. View

5.
McMahon T, Doctor A . Extrapulmonary effects of inhaled nitric oxide: role of reversible S-nitrosylation of erythrocytic hemoglobin. Proc Am Thorac Soc. 2006; 3(2):153-60. PMC: 2658680. DOI: 10.1513/pats.200507-066BG. View